• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»FDA 510k clearance

Can low-dose radiotherapy reshape osteoarthritis care after Siemens Healthineers’ FDA clearance

By Pallavi Madhiraju on March 22, 2026   Medical Devices & Diagnostics  

Can low-dose radiotherapy reshape osteoarthritis care after Siemens Healthineers’ FDA clearance

Siemens Healthineers expands TrueBeam into osteoarthritis care with FDA clearance. Find out how radiotherapy could reshape chronic pain treatment.

What Bayer’s MRXperion 510(k) clearance means for high-field MRI workflow and contrast injection systems

By Pallavi Madhiraju on March 5, 2026   Medical Devices & Diagnostics  

What Bayer’s MRXperion 510(k) clearance means for high-field MRI workflow and contrast injection systems

FDA clears expanded capabilities for Bayer MRXperion MRI injector supporting scanners up to 7T. Discover what this means for imaging workflows and radiology systems.

Why GE HealthCare’s FDA-cleared SIGNA MRI update is more about operations than image quality

By Pallavi Madhiraju on February 20, 2026   Medical Devices & Diagnostics  

Why GE HealthCare’s FDA-cleared SIGNA MRI update is more about operations than image quality

GE HealthCare’s FDA-cleared SIGNA MRI systems signal a shift toward autonomous, helium-free imaging. Explore what this means for MRI operations.

Bimini Health Tech strengthens Puregraft franchise with SYNC as fat grafting scales globally

By Pallavi Madhiraju on February 20, 2026   Medical Devices & Diagnostics  

Bimini Health Tech strengthens Puregraft franchise with SYNC as fat grafting scales globally

Bimini Health Tech secures FDA clearance for Puregraft SYNC. Explore what it changes for fat grafting workflows, adoption economics, and device strategy.

Recent Posts

  • Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes